Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI)

21 May 2014 11:28

RNS Number : 6882H
Bank of America Merrill Lynch
21 May 2014
 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY ANEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS(OR WHERE RI STATUS IS NOT APPLICABLE)Rule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

Pfizer Inc

(c)

Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)

Date position held/dealing undertaken:

20/05/2014

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of anyother party to this offer?

YES

 

2.

POSITIONS OF THE EXEMPT PRINCIPAL TRADER

(a)

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

Common - US7170811035

Interests

Short Positions

Number

%

Number

%

(1)

Relevant securities ownedand/or controlled:

5,573,264

0.087%

7,501,833

0.118 %

(2)

Derivatives (other thanoptions):

100,000

0.0%

0.821%

(3)

Options and agreements topurchase/sell:

11,551,000

0.181%

17,529,400

0.275 %

TOTAL:

17,224,264

0.27%

25,031,233

0.39%

 

All interests and all short positions should be disclosed.Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b)

Rights to subscribe for new securities (including directors' and other executive options)

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

Common - ISIN US7170811035

Purchase

14,902

29.25 USD

Common - ISIN US7170811035

Purchase

3,941

29.28 USD

Common - ISIN US7170811035

Purchase

100

29.365 USD

Common - ISIN US7170811035

Purchase

2,200

29.37 USD

Common - ISIN US7170811035

Purchase

6,000

29.38 USD

Common - ISIN US7170811035

Purchase

100

29.395 USD

Common - ISIN US7170811035

Purchase

703

29.4 USD

Common - ISIN US7170811035

Purchase

2,200

29.41 USD

Common - ISIN US7170811035

Purchase

181

29.481 USD

Common - ISIN US7170811035

Purchase

2,976

29.49 USD

33303

 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

Common - ISIN US7170811035

Sale

28,310

29.25 USD

Common - ISIN US7170811035

Sale

3,941

29.28 USD

Common - ISIN US7170811035

Sale

5,000

29.315 USD

Common - ISIN US7170811035

Sale

12,790

29.32 USD

Common - ISIN US7170811035

Sale

1,000

29.323 USD

Common - ISIN US7170811035

Sale

8,134

29.325 USD

Common - ISIN US7170811035

Sale

15,300

29.33 USD

Common - ISIN US7170811035

Sale

1,000

29.333 USD

Common - ISIN US7170811035

Sale

4,200

29.335 USD

Common - ISIN US7170811035

Sale

13,200

29.34 USD

Common - ISIN US7170811035

Sale

200

29.345 USD

93075

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Common - ISIN US7170811035

Swaps

Short

181

29.484 USD

Common - ISIN US7170811035

Swaps

Long

824

29.319 USD

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4.

OTHER INFORMATION

 

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

(c)

Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

Yes

 

Date of disclosure:

21/05/2014

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY ANEXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS(OR WHERE RI STATUS IS NOT APPLICABLE)Rule 8.5 of the Takeover Code (the "Code")

 

1.

KEY INFORMATION

(a)

Name of exempt principal trader:

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED

(b)

Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

AstraZeneca PLC

(c)

Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc

(d)

Date position held/dealing undertaken:

20/05/2014

(e)

Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of anyother party to this offer?

YES

 

2.

POSITIONS OF THE EXEMPT PRINCIPAL TRADER

(a)

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

Common - GB0009895292/ ADR - US0463531089

Interests

Short Positions

Number

%

Number

%

(1)

Relevant securities ownedand/or controlled:

9,116

0.001%

11,677

0.001 %

(2)

Derivatives (other thanoptions):

0

0%

0

0%

(3)

Options and agreements topurchase/sell:

135,200

0.011%

102,700

0.008 %

TOTAL:

144,316

0.011%

114,377

0.009%

 

All interests and all short positions should be disclosed.Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b)

Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

ADR - ISIN US0463531089

Purchase

1,100

72.24 USD

ADR - ISIN US0463531089

Purchase

442

72.25 USD

ADR - ISIN US0463531089

Purchase

1,600

72.26 USD

ADR - ISIN US0463531089

Purchase

200

72.27 USD

3342

 

Class of relevant security

Purchase/sale

Number of securities

Price per unit

ADR - ISIN US0463531089

Sale

3,964

72.2 USD

3,964

 

(b)

Derivatives transactions (other than options)

Class of relevant security

Product descriptione.g. CFD

Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

N/A

N/A

N/A

N/A

N/A

 

(c)

Options transactions in respect of existing securities

(i)

Writing, selling, purchasing or varying

Class ofrelevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number ofsecurities to which option relates

Exercise priceper unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise Price per unit

N/A

N/A

N/A

N/A

 

(d)

Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

 

The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4.

OTHER INFORMATION

 

(a)

Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"

None

 

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) The voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

 

(c)

Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

Yes

 

Date of disclosure:

21/05/2014

Contact name:

Stacy Otieno

Telephone number:

0207 995 1335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEOABMMTMBTTBFI
Date   Source Headline
1st Apr 20193:00 pmRNSTotal Voting Rights
1st Apr 20197:00 amRNSSelumetinib gets Breakthrough Therapy Designation
29th Mar 20195:15 pmRNSResults of Placing
29th Mar 20197:00 amRNSProposed placing of new ordinary shares
29th Mar 20197:00 amRNSAZ and Daiichi Sankyo enter collaboration in novel
27th Mar 20197:00 amRNSForxiga approved in Japan for type-1 diabetes
25th Mar 20197:00 amRNSForxiga approved in Europe for type-1 diabetes
18th Mar 20197:00 amRNSUS FDA grants saracatinib ODD for IPF
14th Mar 201912:00 pmRNSNotice of AGM
12th Mar 201912:00 pmRNSDirector/PDMR Shareholding
6th Mar 20197:00 amRNSFiling of Form 20-F with SEC
5th Mar 201911:00 amRNSAnnual Financial Report
4th Mar 20194:04 pmRNSHolding(s) in Company
1st Mar 20193:00 pmRNSTotal Voting Rights
1st Mar 20191:45 pmRNSLynparza receives positive EU CHMP opinion
26th Feb 20197:00 amRNSLynparza significantly delayed disease progression
25th Feb 20197:00 amRNSBrilinta's PhIII THEMIS trial met primary endpoint
14th Feb 20197:00 amRNSAstraZeneca Full-Year and Q4 2018 Results
6th Feb 20197:00 amRNSUS FDA grants Fasenra Orphan Drug Designation
5th Feb 20197:05 amRNSUS FDA grants Breakthrough Therapy Designation
5th Feb 20197:00 amRNSEMA grants PRIME eligibility for MEDI8897
1st Feb 20193:00 pmRNSTotal Voting Rights
1st Feb 20191:17 pmRNSForxiga receives positive EU CHMP opinion
25th Jan 20192:00 pmRNSCompletion of divestment of US Synagis rights
7th Jan 20191:00 pmRNSAstraZeneca announces organisational changes
2nd Jan 20193:00 pmRNSTotal Voting Rights
20th Dec 20181:47 pmRNSBevespi Aerosphere approved in the EU for COPD
20th Dec 20187:05 amRNSLynparza meets primary endpoint in SOLO-3 trial
20th Dec 20187:00 amRNSPhase III ROCKIES and OLYMPUS roxadustat trials
19th Dec 20186:31 pmRNSFDA approves Lynparza as 1L maintenance therapy
18th Dec 20189:09 amRNSRoxadustat approved in China for the treatment of
14th Dec 20187:00 amRNSDirectorate Change
7th Dec 20187:00 amRNSUpdate on the Phase III EAGLE trial of Imfinzi
6th Dec 20187:00 amRNSDivestment of rights to Covis completed
4th Dec 20183:00 pmRNSDirector/PDMR Shareholding
3rd Dec 20184:00 pmRNSBlock listing Interim Review
3rd Dec 20184:00 pmRNSTotal Voting Rights
3rd Dec 20187:00 amRNSGrünenthal Agreement for Nexium, Vimovo Completed
26th Nov 20187:00 amRNSUS FDA grants Fasenra ODD for EGPA
16th Nov 20187:00 amRNSAstraZeneca provides update on Phase III MYSTIC
13th Nov 20187:00 amRNSAstraZeneca to divest US Synagis rights to Sobi
12th Nov 20187:05 amRNSUS FDA accepts regulatory submission for Lynparza
12th Nov 20187:00 amRNSFarxiga significantly reduced hospitalisation for
8th Nov 20187:00 amRNSAZN: Year-to-Date and Q3 2018 Results
6th Nov 20187:00 amRNSDivestment of rights to Covis Pharma
1st Nov 20183:00 pmRNSTotal Voting Rights
31st Oct 20189:45 amRNSAdditional financial information-Grünenthal deal
30th Oct 20187:00 amRNSGrünenthal Agreement for rights to Nexium, Vimovo
23rd Oct 20187:00 amRNSAstraZeneca Extends Innate Pharma Collaboration
22nd Oct 20187:00 amRNSLynparza shows 70% reduction in PFS ovarian cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.